Generation Lab Raises $11M Seed Round for SystemAge Longevity Platform

San Francisco-based Generation Lab has raised $11 million in seed funding to expand its SystemAge platform, announced in a press release. The round was led by Accel, with participation from Samsung Next, Zone2, Aoki Labs, BYL Ventures, and Markham Valley Ventures. The new funding brings Generation Lab’s total capital raised to $15 million.

Launched less than a year ago, SystemAge quantifies biological age by analyzing 19 organ systems through primary blood data. The company reports over 275 clinical partnerships and 300 million human-aging data points collected to date. Generation Lab claims a diagnostic accuracy of 99.9% for its system, which is used by academic medical centers, wellness clinics, and professional athletes.

SystemAge uses proprietary algorithms to measure biological aging and identify which organ systems are aging most rapidly. Clinical data cited by the company show measurable reversals in biological age following interventions such as stem cell therapy, diet changes, and exercise regimens. Generation Lab plans to use the new funding to expand access to its longevity diagnostics globally.